

Market Announcement

14 October 2020

Recce Pharmaceuticals Limited (ASX: RCE) – Trading Halt

Description

The securities of Recce Pharmaceuticals Limited ('RCE') will be placed in trading halt at the request of RCE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 16 October 2020 or when the announcement is released to the market.

Issued by

Wade Baggott

Manager, Listings Compliance (Perth)

14 October 2020

Sean Maloney
Adviser, Listings Compliance (Perth)
Level 40 Central Park
152 - 158 St George's Terrace
PERTH WA 6000

By email: tradinghaltsperth@asx.com.au

Dear Sean

Recce Pharmaceuticals Ltd (ASX:RCE) – Trading halt request


Pursuant to ASX Listing Rule 17.1, Recce Pharmaceuticals Ltd ACN 124 849 065 (**Company**) requests a trading halt of the Company's securities pending the release of an announcement relating to Human Research Ethics Committee (**HREC**) Approval of RECCE® 327 topical antibiotic therapy for infected burn wounds.

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Friday, 16 October 2020 or the release of an announcement by the Company in relation to the HREC Approval.

The Company is not aware of any reason why the trading halt should not be granted.

For any questions, please contact the undersigned on +61 2 8072 1400.

Yours faithfully



Alistair McKeough
Company Secretary



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA